Allogene Therapeutics (ALLO) 2 Aug 232023 Q2 Earnings call transcript

Hello. Thank you for standing by, and welcome to Allogene Therapeutics Second Quarter 2023 Conference Call. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be aware that today's conference is being recorded.

I would now like to turn the call over to Christine Cassiano, Chief Communications Officer. Ms. ahead. go please Cassiano,

of and issued our provides a financial available second update operator, today's release market are webcast a Today, closed, and both quarter the for Allogene press our results This welcome you, press call. and website. to on after business XXXX. Thank release that

an limit our will we one per to to remarks, prepared Q&A keep our as as questions call host a many do session. possible. as your we hour We get to Following will ask best this to you and to questions person

President Joining Executive me today and and Officer; are Chief of Chief President Eric Officer; Dr. Development Roberts, David Financial Zachary Dr. Chief Medical Chang, and Dr. Research and Executive Vice Schmidt, Officer.

making financial statements may be and are efforts, guidance, description of and risks among statements. other in During manufacturing current can disclosure change. release data and clinical timing latest documents. be research that and we our certain of regarding SEC ongoing success regulatory subject expectations information, A potential and XXXX today's include found statements and planned presentations, to development capabilities on our trials, will based press are earnings These things. the future forward-looking filings, These forward-looking assumptions call,

cautioned Allogene to these disclaims You these on are and not place any statements update forward-looking reliance undue statements. obligation to

David. to call now over the I'll turn

thank Christine, and you for those you, call Thank the joining today.

lymphoma. I updated on CDXX CAR presented the lead Phase relapse program data for second we quarter, refractory During targeting T our and allogeneic

to complete off-the-shelf appear all responses T ability proud shown generate We to approved durable the therapies. CAR accounts our that has by candidate autologous immensely are be similar product that to

Hematology reviewing options. on of field significant to program, about talk To T then milestone the [ph] the my that a would of current to on June I allogeneic the at ask will focus for Association comments CAR to European state This the CDXX allogeneic field CAR represents in our like Zach advancement opportunity and data the of today including meetings. Society is including and end, at specifically a the presented great T, Oncology, Lugano American I large. Clinical reflect

During the welcome programs our other we within pipeline. will on questions Q&A,

about talk field therapy. let's of First, cell the

CAR proud increasing initiatives address one lives the success as the if of manufacturing many a commercial sales report patients. an developers T T Indeed, Autolus As product. that franchise early detailed has modal there some to ask changing place CAR become this a I of and am constraints, of is therapy, Autolus allogeneic for capable of

CAR On properties fundamentally Autolus more products the hand, CAR than changing base landscape T inherently a and CAR of therapy, expanding the other allogeneic of access. T therefore, represent different that and with T capable attractive modality are

generic former and cell scale. the our between fundamental therapy represents Perhaps never difference the individualized is most the procedure an manufactured that at can that product be

demand. As therapies scale move to accelerating therapies that the is into for potential patient producing will T will Autolus therapy companies at dramatic keep up undergo eligible lines, expansion linear hard-pressed and CAR be earlier with population

undergo disease the secure of the of refractory left cells. market a are for who can patient only progressing and collection eligible who mix that seeing patients myeloma, fraction patients in or Potentially manufacturing successful out to Today, access lymphoma cannot are therapies. of revolutionary rapidly gain with slot, really these patients cannot we a

another to now move community-based lines to therapies to patients centers, which the potential specialized need referred leads earlier T yet CAR from centers delay. CAR T as to Also, oncology be

therapies perspective, this CAR approximately in T figure receive XXX,XXX. will CAR patients estimated who put XX,XXX that By the eligible XXXX, it lymphoma is is will to To estimated number of will it be in T patients myeloma that with or XXXX. grow for

infrastructure manufacturing as and in Several capacity. autologous in individual to few XX,XXX providers as companies are a ability now manufacturing delivery large designed time. the perform to These years' many forecasting increase that are ones, are making investments

could But treatment. from there than unfortunate for even number if even The more be to is be outcome will this can without successful, the that, forecast under forecasted more who of dwarfed optimistic by supply who benefit access patients capacity is the expansion, those, far modality patients treated.

to increasingly scale market addressable lead centered and a life-saving to for simply without a a likely linear not more-and-more model Adding is treatment. will patients large most manufacturing viable which serving access market potentially an

modalities. of or based even My therapeutic T focuses of allogeneic met The disbelief. the on very new biopharmaceutical nature reflection point CAR on are is classes drugs innovative of next trillion industry Often, few products. skepticism $X with

CRADA In approval not Cancer first and the Research that many and would SCADA, know to how forget Development may entered National offer XXXX, the or Agreement lead ultimately of Cooperative many or decline. but Institute Kite biopharmaceutical Kite, opportunity what will but into as companies is same

of now Cacophony The and development multibillion-dollar undoubted a that was required therapies, the in to a overcome The lonely of science. CAR challenges development industry T Naysayers be needed beliefs the Autolus endeavor.

of in CAR year therapies. History Doesn't T progressed towards accumulated, this there itself, Repeat attitude and rhymes. wealth new it was Autolus data modality As but on the a often shift

others are products. We CAR-T excited see are just to but developing from progress not very who Allogene, allogeneic

approaches, that is that is it with a large from companies view for the viability increasingly enter We the arena investment more The sign as more -- becoming better the we modality field. promising the pharma the the see companies, evident. this

from that has have X in but have to work have and fight leukapheresis with master come. worthwhile therapy. need they us excited for CAR-T, our the where recent do clearly A our and must to hard is to treatment trial done it knowledge seen what makes second often keep days access set for the trial us tech to progress bridging can we outcomes The and wait data within Phase we the to not start future patients without or The one, to that is undergo and clinical accumulate are come to allowed none. learnings

one, convenient their and not to product therapy, much treating only the if use physicians. the delivery CAR-T broaden patients CAR-T easier therapy making for way of of provides allogeneic An the and

the often the product is without patients free chronic believe life-saving wider currently potential and line for a and off-the-shelf onetime an a with introduce to Ultimately, the only treatment, the convenience I therapy. community CAR-T cumulative majority way auction to where of setting, to heading hassle return and modality of toxicities while treatment preserving that the again clinic of off-the-shelf lengthy to allogeneic earlier for of careful is again. inconvenience potentially that come the are an the the CAR-T

to the now that, Zach. With I turn like over would to call

you, David. Thank

some autologous noted calls, questions facing importantly, be in allogeneic more efficacy therapies have perhaps of even the the off-the-shelf allogeneic durable can to previous approved complete remissions. and whether an biggest development whether CAR-T an comparable and CAR-T to we of induce product was As safety product

American B-cell Congress that Annual Phase Hematology in from important Malignant and European promise Association the Meeting, Lugano, these answered long-term questions the in our large of lymphoma. durability Lymphoma Society the that substantially Oncology X data Conference candidates demonstrate the International T AlloCAR Clinical product CDXX and on trial very our At we shared off-the-shelf reinforced

ALLO-XXX lymphodepletion received process ALPHA These a with or ALLO-XXXA XX received the of and relapsed/refractory patients single X a at comprised being ASCO, following in the cyclophosphamide of is doses FCAXX, of is manufactured dose patients standard of using of alloy plus XXX. XX regimen low milligrams fludarabine LBCL which all an potentially presented who the our deployed analysis At ALPHAX CAR-T-naive regimen an EHA, presentation trial. we focused and trials that of pivotal Oncor updated with on Phase

XX, The The data from and patients months. X the the XXXX response ongoing patients days. through median time five months enrolment were cut-off, had three a of the XX maintained or all month XX achieved who an of start of XX% patients a XX% months. followed of through or progression April and therapy patients in at Of to five was XX CR fifth patient minimum CR or And disease as XX% at complete had a are remission. six six six.

remaining was in over remission three of XX longest duration months. months for months median the XX remaining The remission with for XX.X over and response patients in

these to label. range rates our data can rate light of autologous per of viewed approved CR put XX% To that XX% CAR in CR therapy in from XX% context, be T

the responses can therapy be T of CAR complete durable. appeal is Of that course,

XX% Our ALLO-XXX manufacturing autologous at favorably the of XX%. approximately we to in CAR XX% month made process. from with the range CR received presented ALLO patients six using with At all Lugano, compares LBCL rates XX T rate or XXXA who from as meeting their data relapsed/refractory

of of patient one who no our therapy. either received addition doses patients, patients data two month patients additional Across included of and or consolidation faced the in received this patients ALLO-XXX XX regimen. to reported per these XX set XXX% XXXA received data ASCO, product ALLO-XXX In lower approximately specifications apart infusions at bridging

a T patients, optimized XX% at response XX by patients of within duration established six. the achieved patients less even autologous XX response months, of XX was still ACR these demonstrating therapies parameters XX.X maintained was In complete that by XX in or these also could we achieve whom dosing. results The month median using approved CAR

responders, We also first off-the-shelf observed robust for arguably persistence allogeneic product. and an patients, expansion a cell particularly in cell in CAR T

greater all in were tolerated ICANs In was GvHD. LBCL ALLO CRS incidences T with therapies of and manageable of comparable our with received CART and well or autologous included LBCL. infections cases all no XX experience no safety who the Naive CAR or generally patients X Treatment product. relapsed/refractory presentations, with Cytopenias analysis patients and to Grade

achieving therapies, patients into providing the counts within infection of rate. showed infusion and comparable autologous with levels additional We to recover to lymphocyte similar first kinetics beginning insight cell neutrophil our and month baseline

allogeneic for the competitive complete data remissions CDXX potentially demonstrate durable approved are set potential to to and autologous the to the CAR first CAR Ts. CDXX stage induce an T profile of a Our

turns Our for objectives two program. to focus now this important

trial, to establish enrollment this hope the of AlphaX new where Phase The X first potential we the modality. being in ongoing definitively

expect very have trial enrollment and are Europe extended in pleased year-end. this before Canada Australia to and to in into enrolling begin patients QX in We

of Phase which to regimens regimen LBCL. working of earlier approval the over ALLO. continue EXPAND a parallel, in through focus designed line also a enrollment containing that In we trial support X in lymphodepletion on design We is FluCy regulatory demonstrate to are could trial our strategy superiority ALLO-XXX

the year. may and proposed fallen have cells this approach short and particularly the to support attributable to elimination. We look success where believe the end to our by our our be expansion of advantageous T detail tumor may sharing achieve to others more persistence our of to on is forward CAR durable ability date, allogeneic strategy believe We necessary

already doses monoclonal an FluCy. antibody we've improved with presented data of clinical from program our low our when ALLO-XXX, performance they of CDXX preponderance include point The anti-CDXX to standard

high with permits by extended even ALLO-XXX, severe might persistence. What window doses with does CAR chemotherapy and of enabled that expansion of associated be platform cannot toxicity. cell Our an be T ALLO-XXX reproduced

We of our enrich to trial. rigorous solid utilized T works as investigate focused practice technologies, the on ALLO-XXX persistence of our what next-generation currently in is tumor we and a which boundaries CAR are cell including understanding as expansion now applying approach explore anti-CDXX Dagger, to being the best

the I will Eric. now turn call to over

Thank past rewarding, five years you, exponentially. to by that Zach, drug build Allogene, to I'd have They teams allowed and I of challenges, day last the acknowledging bittersweet that relationships fun. must could my at to begin have opened development like side everyone. the been afternoon, intriguingly have my management and and life-changing and do not The respect a is exciting what for I very and a provided good perhaps new me of today grown eyes most fathomed. complexity decision-making previously occasion. industry

been progress David and following -- family. the more me look spending they my I to Allogene in of to I reality part of patients. New to time AlloCAR am with the has be the of serve T it and recorded the will promise the thankful trust company's turns Allogene. look CFO privilege for to It forever for a a as a opportunity to have into forward and be team the forward truly will as York me.

$XXX.X ended June Now I'm pleased on sheet very XXXX, balance with healthy. remains million and that equivalents XX, investments. financials. in We share cash, cash to to our our

ATM efforts have XXXX. our to our facility. addition or operational runway we into current of at-the-market net raised half financing believe efficiency, the second our approximately equity from $XX million expectations, In we in on second proceeds cash to ensure we extended Based the of quarter our

non-cash quarter stock-based second research development includes General second and XXXX, and $XX.X the expense. includes million XXXX, of $X.X which stock-based expenses were for quarter million $XX.X expense. the In of were expenses $X.X million of million our non-cash compensation compensation of which administrative

including share, XXXX of quarter second $X.XX stock-based $XX.X non-cash million. or the million for was loss net $XX.X compensation Our per of expense

expect $XXX million decrease XXXX. equivalents investments We continue approximately a of in to cash, cash in and

estimated GAAP million, development XXXX from compensation year any which excludes full to approximately $XXX expense potential This be $XX approximately impact stock-based our includes of guidance operating expenses million. expect We business activities. non-cash

will With call the for your that, questions. we open now

first Thank from Cowen. TD you. with the Baron comes [Operator Instructions] line Van question Our Tyler of

Your line is now open.

Great. I'd for said, and to your the you Eric, recent pace pace all like helped Good is, whether with in the seen much taking congratulations, afternoon my an that increase ask very question especially achieve all on you conference during the on to With allergy. company ALPHAX at the of presentations. elaborate the and of Thanks in enrollment guys. question enrollment, that tenure you've

for Thanks the Hi question. it's Tyler, Zach.

the in guidance next that the first expect is we year. we of that maintaining half enrollment complete guidance have provided today. So We're that to

change pace towards the of the always enrollment clinical that pick to we time, period expect for enrollment think over trials. to the end going is and very standard I up is see enrollment of

Australia Additionally, the the year. EMA the sites the the And to open our coming approval in weeks. sites of that add roster plan to furthermore, gotten do and enrolling expect of we have in end to to by by we Europe,

all terms study the are -- building pointing signs the of by in have enrolled in the in the direction expect we geographies online, coming So, momentum half. first to of

Thank you.

comes Goldman line Sachs. Salveen question from next Our Richter the with of

now Your open. line is

Good [indiscernible] Salveen. on afternoon. This for is

a us. two-part from Just question

respect line the ongoing is space, the optimization thinking BCMA situation CAR described clearly also of given evaluate in to program, was that especially competitive earlier that's asset the like the with then I the Caribou the in supply T data I you. required you CAR the prepared from context, for landscape seems ALLO-XXX. autologous you And As to about guess are improving, remarks, Thank T. this in which CDXX recent in lymphoma it context presented starting the guess, in how patients. is with

is David This Chang. Yes.

first the I'll BCMA, the and to Let Zach me on comment take ask question on competitive data. the

But there are to you're T In along with reducing is this terms out some that's mean, that definitely manufacturing of it's of that expecting hearing putting mean, certainly, of commercial is also a a materials And spec, to leads I which lot hearing CAR as lot increase happening autologous patients. the improvement are we to the capacity. pharma we to been of able happening, the in the as pace the how that following we of supply, I not and provide is being that that were I ramp-up space in that, expected. is to think has what effort needed. be time happen. is There will

you program. asking Now are I think, to, that really our what leads BCMA about

to viable components that mean, do. look for always product to one the continuing hoping are self certainly, maintaining that and manufacturing also we knew are process, the of to I the opportunity is of key We efficacy improve we level making manufacturing the the of

a continuously as complete the what Zach are will we CDXX? making we with good manufacturing BCMA we're So program on reviewing review. progress, be doing the we and

Yes.

presented we that for stand now see the much in cells. T very at great but as this question overall additional growing field. sponsor, very a AlloCAR of data some join data update. that patients. five arguably and a this we validating the summer off-the-shelf Overall, the So, to were an Caribou we an And been also this another years cells milestone we this present pleased most part of by very off-the-shelf allogeneic and use in are having supporting in the is see this for to platform T of experience field, very experience and driving the alpha/beta benefit field, We for about person see the proud

Thank you.

the Our next question from Michael comes Jefferies. line of Yee with

is Your now line open.

thanks guys, for the Hey question.

fit particularly the that, the To Yescarta. of up envision one One study. an to a there's you And about CAR-T be product is second-line shelf. earlier things would the that need your obvious that, do uncertainties after lines, would of run off comes could that given use since

design on think help there think the give remind about you progress company a Maybe third think pharma you year. actually than start that more insight how the that's important would because to a Could second-line you you you us about and But can different have you. make how later that? us, even year? that line? would a into money Would challenges lot second having easier? to of talk things of to third relevant through do line. Thank should out a some just you you suggested, would next could Are I for line, sort You just tidbits some study this

take of question. me let the part Mike, the first

all to is study design, excellent questions. asking comment and much which on very on Zach were important ask And You I'll track. the

treated opportunity to treatment line, benefit really the the lead In really patients to the terms requires that mean successfully oncology maximize where grail do lines cell similar what the to of therapy to the the potentially cure, second, third trying no of the of that subsequent is -- think I space. are that's therapy. I earlier or a onetime longer that's holy something in of of can we

in setting, think we of when patients how these -- the by oncology I earlier the most infusion in are mean clinics are as and patients for oncologists. the the I that And but is as in line what mean, well cared tertiary local local careful about centers, not

to think the this off-the-shelf CDXX allogeneic relapse and where And also really the setting beyond see we are our is that's we of in program And third-line benefit march refractory we trying about current so CAR-T where shining. the setting. as

investigator regulatory holds. plan for design, launching sometime to the we agencies and finalize been study get Previously, XXXX. we've the from the that look still with in That input the work then guiding will study

comment ask to that. but… let of It's early, Zach study terms design, In very on me

Yes. Mike, the question. for Thanks,

So, it I on. think premise the spot of is

across that of learning I also patients these their compelling, utility obviously, powerful CDXX you are as there. so. numbers think And more not for as and therapies look and in we're are as the lines what relapsed/refractory is if disease, earlier BCMA is in greater

So, that design not to we serve exists keenly we're And I unmet in will with our that been that need to to do study for that this be and study. strengths suffice have up of lines think lot great Allogene field hope coming that year. we an think say, by particular. to details it is We a a focused share yet But in to line. this also of on the for ready able play end earlier second and the quite a on this opportunity in

Thank you.

from line Cheng next comes JPMorgan. of the Our question with Brian

is open. line Your

Thanks my guys. Hi, for call. taking

that exploring solid the mentioned technology You with DAC CAR combining you're tumors. of thinking in human

need your a as resources Is T-Cell. of today of potential And your is the be you since does efficient into Just current strategy to on more set CDXX. this BDA on for next the timing play exploration most fit portfolio? How focus now of

has ability And integration, players the evolved include are engineering, the that's whether you transduction. CAR Brian, think is cell is I therapy And really cetera. This early Dave gene very et the questions. possibly to doing multistep potential excellent I to about it's the therapy asking we stages the Lentiviral autologous engineer therapy cell a cell editing guys essentially whole. technology, are Chang, of in what we site-specific something for et gene T we to field Today, mean now. cells, this and allogeneic, this that in the I how case, right cetera, therapy when is think are including the cell gene as mean through available of here. say can still

therapy accomplish. in is And that grail allogeneic just field really not cell holy the everybody the to us, trying cell that's of

field. where the programs cells also we context, the questions. the of that we some is but concept So the the we are than outpatient answer administer better, And provide discuss not in work make to see don't I we to advance internally that these the lymphodepletion, as turkey the how reduce all this necessarily trying advancing next to things as mean to that make of are that Dagger solutions potentially technology the generation such that's more can just we consent. easier all [ph] the and

do mean, something the about spending the address a we that question as the this of are same trying to how environment I very the we where through this accelerate as one. as not as this in And highly Mike situation was current are things much capabilities necessarily further well by we point. as to that The is prioritization resources scrutinized bringing asking do good may trying at question. we is can is -- in another a well is partnership to have efficiently. kind also, do could trying any additional where And what

Thank you.

Our with the Schmidt next of question comes line from Michael Guggenheim.

Your is line now open.

lot kind capacity capital for launches. of Congrats, building they're of on for of Michael. I into on first, a Kelsey then in allocation. fit guess, of T, on still biggest or something how but is of eligible specifically on capacity question, building course, And just -- in Notch day, quick DLBCL, had small does see CAR about else? This the guys. percentage the your David, much. to the early go. a sad stricter factor, the questions. that it guess and Eric, partnership hear maybe your patients limiting Thanks Hi, myeloma, couple a I remarks, you last we is there's last actually I getting kind is But because prepared so

truthfully, about what space the follow we happening information in in companies -- think the question the basis. The the Yes. quarterly large on autologous, this I in what's released

So as do. know as you information much we

setting, third-line about was XXXX. by the made are the eligible some estimate line that patients that I therapy. of mean of CAR-T only space bottom pharma CAR-T receiving in the that are in that making The the are is in XX% is, the remark

has of in how trying getting usage line. the of line there XXXX, patients earlier that up-tick how who quarterly on terms are third been due may triangulate release And CAR-T. and in the some versus also to gone to revenue up percentage eligible is further much penetration and looking are earnings in of Now the have much patients the we the

that, but talk especially other only hematology not do to the access with oncologists, that also top we On CAR-T. the at centers not have of commercial CAR-T experts,

certified still in centers limited. the Let's used be number certified CAR-T commercial centers the can and that reminded, is administer is only supply of

as your well still eligible question there answer So, are somewhat as well, to patients a who that lymphoma my is of number current access is number to space. but large sufficient the not as comment are non-Hodgkin's in is our getting guesswork of who estimate a the CAR-T in

The what second do, is. the incredible by horizon, really part the what differentiate are doing. difficult of mean and Notch terms can be humbled but in is the terms doing into are that always in an grail is to be time cell power functioning of we this has the cells holy question may to scaled able with of I Notch it up of technology of trying something and the been sensitive T area field how iPSC leveraging be the iPSC realistic that I'm clinics. really we And introducing that

next mean, I thought in the the X iPSC the CAR-T. in be to less will I mainstay years, XXXX, more or back of XX in XXXX,

I therapy in XX time can that CAR-T from and several the think are before the it's clinics. years years We still, IPS-derived about be

working a with just but we the think in how taking notch partnering is future definitely and I it's a putting are we the and definitely there, mean context are time I of

you. Thank

line comes next the Our with Canaccord. of Newman from John question

my Thanks guys. question. taking for Hi

I'm the enrolling is otherwise here, in to the any autologous regions getting think and the those asking that just Europe wondering there's The increase that if or of you're pivotal study that I you're if patients be of difference patients availability CAR-T Australia patients going I'm talk about chances autologous mentioned therapies whether be in in perhaps year. end Australia I'm really in getting shortly by therapies. the question the you curious So reason two would you not in Thanks. the could there. enrolling could the Europe

Yes.

overtime, those change. significantly it the CAR-T regions expect of is in know utilization obviously, States. in less And So that will than that the common we generally United we is that

as board therapies line and to or as in T CAR towards on utilization And in well. sets table line. these whole data second come to approve moving The payers third additional the begin is regulators of field get pivotal and and

But these States. behind regions are significantly United the

substantially United is, there the of is the third higher than States. where it in plenty of is patients So in need both regions unmet in line those

So time regions. that we that, to bring a to felt it current be not those of have able that feel made in ex-US broaden footprint needs standards being a and long -- for are lot those and it's by met patients the whose are sense on

Thank you.

Our next question the Allen comes from line Jack of with Baird.

is line now open. Your

Great. work I your to last for Servier Congratulations years. talk congratulations Eric, second progress to five over day a accomplishments, the wanted you the of here. to and all And about on on last to the your I'm try to team my going the on you to do relationship. put best to

stand seeing Servier minimis XX-Q us that the quarters couple remind that maybe it you or of last things how Servier? from de here. you And in to the in the I'm as XX-K very Could relates received payments

those guidance the that Thanks region European And move it relates baked into much. could study? ALPHAX as the so in relationship be with surrounding expect there? the to payments as the higher, you you Servier Do cash what's and flow

Servier your kind, it's did hear must spot very high Jack, on. school, you And good your in pronunciation much is think personal studied of I than to more I question, thank have French comments and because the voice. for you the

of Servier, of our a certain challenging discussed have a in previously over and with disputes collaboration. our we've little continue SEC relationship to We bit are as aspects filings. There

opt as this there disputes a to noted, as matters. delve cost entitled so, you believe rather well recoveries, date, we're legal are future into over to As in in point ex-US we time ability into development which than our to at

what's terms be to find going in the of forward. in it And leave able update. solution be So XX-Q hopefully, to we'll our I'll going just published to an eligible

Thank you.

Our from the Goonewardene with Asthika line of comes Truist. next question

open. Your now is line

-- more some looking Asthika. question of is great. And on If I a to Hi. get to cytokines wanted know can are the you culture you nascent change that color I -- to trying ALLO-XXX. guys be more a self-phenotype? looking share get would well, if just used tighter a you This for are Carvykti are guys days the on Karina get as had on, timing to efficacy? the know, to guidance you

with in are without say process cytokine there your I as things reviewing we an the BCMA multiple of about will terms important Karina, And going what what of we timeline of as pointed that are question we into is And aspect doing are program. our Yeah. review. details. out, further manufacturing

will, Let's the that and into we decide clinics. what complete we will we the back introducing think about when until review defer

Thank you.

question next comes the from Patel Riley. line with Kalpit Our B. of

is open. linen now Your

afternoon. report study? sites the Yes. question. study comment you the for the the Hey. this taking Thanks is roughly the enrollment. the Could unchanged how EXPAND trial? data more the for on additional And as please to you clinical many on One time to ALPHAX Good from with guidance still expect include around same

you question. Yes. the for Thank

ALPHAX gone haven't the on EXPAND. So sites either detail number into of we exact for

America are on for to EXPAND. sites bring continuing We in North

this newer know, a is you ALPHAX. than As trial relatively

of benefit the there. have long-standing Phase sites X didn't we relationships So with

to asked is ALPHAX. also EU as as the have the from same scratch. online do intend we similar starting time last both bring expect that for EXPAND Australia. up coming you So everything And Yes, are the we But correct. data about coming roughly point still And ALPHAX, to plan is for speak. EXPAND we to into sites and

you. Thank

with comes William from line the next Our Sami Blair. question Corwin of

is open. line Your now

Hi, for question. there. taking Thanks my

thinking are large partnerships commercial pharma are you'll you you Given about through do that the pharma. ALPHA-XXX commercializing you T a guess, large need -- or CAR commercial alone how therapies are with partner? by I current commercialized or think players

that, me and say mean, I way take discussing, let think information. Sami, will I we the something going we the and little that how Yes, early that bit we're one it's a to great furthered for to are question. too commercialize, share other. position we think or that's But internally once I us

Thank you.

of Issi RBC Capital. next line Our comes Luca from question with the

Your now line is open.

gives question. prior if can back much talk for bit so question. circle both confident you EXPAND. enrollment taking I my ALPHAX a Can projections just may versus What Jack, rolling complete first of little Thanks again Great. something a enrollment thoughts EXPAND about in help all see you that. then, for you much you chapter. hear your the on in And harder on ALPHAX, but all I thanks Eric, and love best Maybe, the than in trials enrolling your half out to for next XXXX, would your

Thanks, Zach. This Luca, for the question. is

time. required We actually the study to said. roughly specified So our We've when expect the that the enrollment. well the be the endpoint in -- we've that fewer to these we each But as about based take are trials, of available are same to we exactly ongoing patients current complete that enrollment of we belief will by as next guided projections enrollment our to EXPAND will of ALPHAX haven't study -- -- but two the actually of half that think between we data first study to at currently, year. completion time come as is of EXPAND sets enroll do designs with less those that on

you. Thank

comes with question of Butler Our Hutton. line EF Tony the from next

line Your now is open.

a Thanks. the were possible you But fatigue because any statements demonstrated so consistent and address make publicly any Thanks very very there patients? I in other opinion a asking -- wanted this much. CRS go lower dosing presentation, I that given you so who is for at again, minimal we're to -- the million as is we're two available patients data -- And it's side had question best. thank that been time. question at syncope ACR, effect employed am my has number minimal believe but being occurred and wasn't importantly, at for Dr. of all are and/or the or doses. asking, don't for there patients or and much, good efficacy Eric, there the about, was to the And if data whether And understand not finally, in with is, any David is can number I I'm in cells. has was they're XXX Zach, studies. that I The what the very profile may. data I so Dagger, Sauer’s to diagnostic back you

the for you Thank question.

assessment trial. to are I at been with as into agree to said we're and -- is much we continuing finding beyond data don't with are could be enrollment from treated very has though, true We do certainly been this we details of that patients dose we shared your as this want many about or superior able the at now. get -- expect AACR today, trial standard that AACR still And what I later and that, continuing So patients is to the to care. what other of part the these share was compelling how AACR. dose have publicly from And exploration each additional at shared information expect than on.

Thank you.

question of Singh the comes Akash line next with Oppenheimer. Our from

Your line open. now is

rates with and about of sort whether figures the or are BNA from And – it's for ? ALPHAX question, the comfortable what have to when also you. of activity or of luck. Thank you question. you. a follow-up wondering dosing terms that which Thanks out Thanks looking duration make to read XXXX, you commercial but patients then what's good the -- you're ballpark of Great. that for of question. of Eric, given what in I Thank to question with is BLA comfort Renew, a enabling I thinking FDA for The discussions activities, mean you the was [ph] would not a that minor enable sort comparison, response. a And there just are just you looking sort best out previous facility? I your -- you would in ALPHAX what's later just lot, your response is give

data is So The which the positive have the take trial that program maybe to June think both those comfort again, so experience really, from conferences in what's us the feedback various I since we are involved all the one. I, Phase was and in Phase we giving surface II not. I'll primarily, brought -- share there overwhelmingly about that been are first of investigators, the from where at it's the and that those

criteria And so the program. patients are that in for Phase meet those II our eligibility

of going filling to David, the don't FDA, forward. into a our this you want hand get sort landscape currently question. we specifics prepared conversations that facility Maybe of in I'll previously with all but And view the it to about limitations that's alluded for access much-needed David is so think remarks. I niche commercial the given And to that the in

Yes.

question dosing. patient So is the second about

contract produced communicated, the from that previously dosed has study the in being have patients to in that are we Phase our materials currently we the way the manufacturer treated As have patients I

Thank you.

comes next Our question line of the JMP from with Kishore Gangangari Securities.

your check line open. Please Kishore, button. your open. now is is line mute Your

Hey, Reni hear Benjamin. you this is me? Can

Hi Reni.

as from, like companion I I where do taking all for Kishore the the XXXX. you view the thanks world that's future and to your have next the best at more process? predicted bit the talk of dose can you'll hemological studies? main of you driver the of have guess, the Thanks. of what value. but color finally, that value the I'm how as ALLO-XXX. curious, they year? shareholder have But -- And identifying by escalation you how of kind in question. the by think real got regarding complete than many in Hey, end driver end looking to kind do the you're in-vitro patients diagnostic, I you question little with Are endeavors. know a might of Eric invasive provide different has don't from I kind this, The is you expect patients that

the to allowing evaluation. it's first that for not enrollment biopsies you that biopsy, is taken on were companion can diagnostic, question the but it So -- mean a we're I I tell study prior

But original us prior requiring is giving recent fresh are a are diagnosis operation or that patients material some biopsy. accessible. from their of blocks no others So, many biopsies if just there's

So in in sort invasive day every that regard, other than of more any that tissue it's occurs assessment no oncology.

second And surprises what literature. the seeing The been no. we're part results we'd finding no are with of differences literature, that is then to question very there. the is tests these -- in consistent question that answer second we there's the What from of have so expected the the was, and question

the It's of was, weeds ACR the as number patients, again, presentation. far But the since. the here and very have second I -- high for get ever that on As expectations future in updates. high, want spiked remained interest too program after again, this the into setting don't we question, is what to the

of in putting the interested abundance trial. are to who on And so, there's interested abundance been an investigators of who patients are in patients

you. Thank

comes Securities. from with the question of Jason next Bank of Our line Gerberry America

Your open. line is now

so your centralized is companies in wanted perspective forward approaches the CAR-T in. you to moving autologous on And linearly to me come impediment had I Galapagos. being challenges model get comments a squeezing see for wanted the pacings what question earlier to I autologous as by like for the like site Thanks guys. Hey manufacturing? with back the point scaling about of David. of biggest really of just explored like just like

scaling? Thanks. do that see hurdle what So and sort of to operationalizing you biggest the as

product therapy. test about question. I the therapy point manufacturing respect at of dimensions. before has companies obviously, is a care when that Great I to of think Obviously, picture early But to cell how and a advance my allogeneic view, about mean, are coming asking. don't that's I used of thinking out. think questions manufactured leukapheresis up. it -- used human, cell Patients autologous have and Yes. are barrier to as really and how the be as can somewhat comes T about you And are or part do waiting you're products the like days, release quick process the therapies be in I proposition the has any human. One are have therapy, that be of have time. where the to sort that's in undergo these these to all same things questions, the realize potential to all clear cell different autologous going play sometimes CAR provides, the the I well exact And that multiple manufacturing for to other manufacturing of of in have full one a value there

you. Thank

the from line William comes question next with Pickering of Our Bernstein.

open. now is line Your

far might you're an a the administer commercial time much the autologous rolled squeezing your horizon able that to I expectations In in as access can trying at are in. might more, for Good your what And where when dosing market setting? hospitals some head-to-head not Thank expectations how be if ask that much a for of be segments trial? autologous? these are hospital, seen to how you. don't allogeneic today, you your one such competing study, out what outpatient basically And therapy me morning. community you understand for be to Thanks with CAR-T have just so so for in potentially maybe common ALPHAX

Hi, Bill, question. great

to. too the early. setting allogeneic want in to And I at the ongoing In all mean, outpatient as information, our this dosing, in about we patients, be I question that, the we that. it's more mean, but we I studies think patient terms I the second programs more to and that think take terms allow our to relatively of of provide direction treat will that's able

point, So still at early. this it's

So stay tuned.

Thank you.

Our Burnett next question of Stifel. with from comes Ben the line

the can This our diagnostic, CDXX talk expression? have IHC type mentioned wondering to Is diagnostic you are to in to is would Ibanez that conduct appreciate planning you vitro a A you you plan Burnett. if taking ALLO-XXX, for for on how based. assay heterogeneity and Thank you. if Thank for this in and question. tissue designed Ben companion follow-up this account Ventoso you centralized you for also on Carolina assessment,

So is it assay. an IHC-based

an that score the And opportunity and to gives address and so understand us heterogeneity.

that the of development we've the So in assay account taken into

like over Thank question-and-answer our for the you. to I any additional would back to management That session. turn concludes conference comments.

you very today. much call joining for Thank our

to our advancing now you to that hematologic pivotal on demonstrate to continues focused may allogeneic CAR-T Operator, great We remain potentially disconnect. industry's patients order access first cancers. And data promise in AlloCAR off-the-shelf the we in both CAR-T. T CDXX enable trial more are thrilled

This thank disconnect. Thank you. the off now participation conclude and Ladies and in gentlemen, today's conference. may and for you you log your does program,